• +1-646-491-9876
    • +91-20-67278686

    Search

    Gliosarcoma-Pipeline Review H1 2017

    Gliosarcoma-Pipeline Review H1 2017

    • Report Code ID: RW0001834405
    • Category Pharmaceuticals
    • No. of Pages 187
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Gliosarcoma - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Gliosarcoma - Pipeline Review, H1 2017, provides an overview of the Gliosarcoma (Oncology) pipeline landscape.

    Gliosarcoma is a type of brain tumor that originates from glial cells. The tumor grows rapidly and symptom will vary depending on the exact location and size of the tumor. Most likely they may be headache, vomiting, cognitive problems, and drowsiness. Treatment of brain tumors depends upon the type and staging of the tumor, its size and position in the brain, as well as the age and other health problems of patient.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Gliosarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gliosarcoma (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Gliosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gliosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 14, 10 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

    Gliosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Gliosarcoma (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Gliosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Gliosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Gliosarcoma (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Gliosarcoma (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Gliosarcoma (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Gliosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 3
    List of Figures 4
    Introduction 5
    Publisher Report Coverage 5
    Gliosarcoma - Overview 6
    Gliosarcoma - Therapeutics Development 7
    Pipeline Overview 7
    Pipeline by Companies 8
    Pipeline by Universities/Institutes 10
    Products under Development by Companies 11
    Products under Development by Universities/Institutes 13
    Gliosarcoma - Therapeutics Assessment 14
    Assessment by Target 14
    Assessment by Mechanism of Action 17
    Assessment by Route of Administration 20
    Assessment by Molecule Type 22
    Gliosarcoma - Companies Involved in Therapeutics Development 24
    Agenus Inc 24
    Bristol-Myers Squibb Company 24
    Celgene Corp 25
    DelMar Pharmaceuticals Inc 25
    ERC Belgium SA 26
    Merck & Co Inc 26
    Merrimack Pharmaceuticals Inc 27
    Millennium Pharmaceuticals Inc 27
    NewLink Genetics Corp 28
    Northwest Biotherapeutics Inc 28
    Novartis AG 29
    Nuo Therapeutics Inc 29
    Progenics Pharmaceuticals Inc 29
    Tragara Pharmaceuticals Inc 30
    Gliosarcoma - Drug Profiles 31
    ALD-451 - Drug Profile 31
    alisertib - Drug Profile 32
    avadomide hydrochloride - Drug Profile 38
    BMS-986016 - Drug Profile 40
    dasatinib - Drug Profile 42
    DCVax-L - Drug Profile 45
    dianhydrogalactitol - Drug Profile 53
    DNX-2401 - Drug Profile 68
    ERC-1671 - Drug Profile 72
    flucytosine + TBio-01 - Drug Profile 73
    G-200 - Drug Profile 74
    indoximod - Drug Profile 77
    irinotecan hydrochloride - Drug Profile 83
    irinotecan hydrochloride + TBio-02 - Drug Profile 95
    lonafarnib - Drug Profile 97
    M-032 - Drug Profile 99
    marizomib - Drug Profile 100
    p28 - Drug Profile 105
    pazopanib hydrochloride - Drug Profile 107
    pembrolizumab - Drug Profile 115
    PSMA ADC - Drug Profile 167
    RRX-001 - Drug Profile 171
    sapanisertib - Drug Profile 173
    SGT-53 - Drug Profile 176
    TG-02 - Drug Profile 178
    urelumab - Drug Profile 181
    Gliosarcoma - Dormant Projects 184
    Appendix 185
    Methodology 185
    Coverage 185
    Secondary Research 185
    Primary Research 185
    Expert Panel Validation 185
    Contact Us 185
    Disclaimer 186

    List of Tables

    Number of Products under Development for Gliosarcoma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Gliosarcoma - Pipeline by Agenus Inc, H1 2017
    Gliosarcoma - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Gliosarcoma - Pipeline by Celgene Corp, H1 2017
    Gliosarcoma - Pipeline by DelMar Pharmaceuticals Inc, H1 2017
    Gliosarcoma - Pipeline by ERC Belgium SA, H1 2017
    Gliosarcoma - Pipeline by Merck & Co Inc, H1 2017
    Gliosarcoma - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
    Gliosarcoma - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
    Gliosarcoma - Pipeline by NewLink Genetics Corp, H1 2017
    Gliosarcoma - Pipeline by Northwest Biotherapeutics Inc, H1 2017
    Gliosarcoma - Pipeline by Novartis AG, H1 2017
    Gliosarcoma - Pipeline by Nuo Therapeutics Inc, H1 2017
    Gliosarcoma - Pipeline by Progenics Pharmaceuticals Inc, H1 2017
    Gliosarcoma - Pipeline by Tragara Pharmaceuticals Inc, H1 2017
    Gliosarcoma - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Gliosarcoma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Agenus Inc
    Bristol-Myers Squibb Company
    Celgene Corp
    DelMar Pharmaceuticals Inc
    ERC Belgium SA
    Merck & Co Inc
    Merrimack Pharmaceuticals Inc
    Millennium Pharmaceuticals Inc
    NewLink Genetics Corp
    Northwest Biotherapeutics Inc
    Novartis AG
    Nuo Therapeutics Inc
    Progenics Pharmaceuticals Inc
    Tragara Pharmaceuticals Inc

    Request for Sample

    Report Url http://www.reportsweb.com//gliosarcoma-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//gliosarcoma-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//gliosarcoma-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments